Almost No Medicare Plans Cover Wegovy or Zepbound. Check Yours Before December 7
Author
Date Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
If you're on Medicare and hoping your drug plan will cover Wegovy or Zepbound for anything other than treatment for obesity, a new study has some hard news. Researchers at USC and the University of Georgia found that Medicare drug plans almost never cover these two drugs when prescribed for their other studied benefits (such as sleep apnea and reducing cardiovascular disease risk). That's true even for the heart, liver and sleep apnea uses they're approved for (USC Schaeffer Center).
Medicare open enrollment ends December 7, and the plan you pick now usually sets your drug coverage for 2027. If you're counting on one of these drugs, now's the time to check. We'll also walk through how the $50 Medicare GLP-1 Bridge fits in.
Who This Helps
This is for anyone on Medicare who takes, or is thinking about taking, Wegovy or Zepbound. It's also for family members helping someone pick a plan this month.
Why can't Medicare just cover these drugs?
By law, Medicare drug plans can't pay for drugs used only for weight loss (KFF). That rule doesn't apply to diabetes, so diabetes drugs like Ozempic and Mounjaro aren't affected by it.
Wegovy and Zepbound have other approved uses, though. Wegovy is approved to lower the risk of heart attack and stroke and to treat a serious liver disease called MASH. Zepbound is approved for sleep apnea. Medicare drug plans are allowed to cover them for those uses, but they don't have to (USC Schaeffer Center).
What did the new study find?
Most plans chose not to cover them. From 2024 through 2026, not one standalone Medicare drug plan put Wegovy or Zepbound on its list of covered drugs. Among Medicare Advantage members, only 1% to 2% had coverage in any given year (USC Schaeffer Center). In a news release, co-author Alice Chen said "the vast majority of Medicare beneficiaries who qualify still lack access."
Even when a plan did cover them, it often didn't last. Among people in plans that covered these drugs in 2025, only 16% still had coverage in 2026, mostly because the plan dropped them. No plan covered them for all three years. So even if you're covered now, don't assume you will be next year.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Why do plans leave them off?
Cost is likely a big reason. KFF reports that covering obesity drugs in Medicare has been estimated to cost $25 billion to $35 billion over 10 years (KFF).
Plans also carry more of the financial risk for expensive drugs than they used to, and many rely on prior authorization to control who gets them (AJMC). An expert from the Academy of Managed Care Pharmacy told AJMC that falling cash prices could eventually make coverage easier for plans to keep up. He hadn't seen that happen yet in 2026, though.
Where does the $50 Medicare GLP-1 Bridge fit?
The Medicare GLP-1 Bridge is a temporary program. It runs from July 1, 2026, through December 31, 2027.
If you qualify, you pay $50 a month for Wegovy, Foundayo or the Zepbound KwikPen. Your doctor needs to send a prescription and get prior authorization (CMS). The Bridge works outside your plan's drug list, so your plan doesn't have to cover the drug for you to use it.
To qualify, you need to be 18 or older with a BMI of 35 or higher. A lower BMI of 27 or 30 can also count if you have certain health conditions, like prediabetes, a past heart attack or stroke, or kidney disease. Your doctor also has to confirm you're using the drug along with diet and exercise (Medicare.gov). You still need a Medicare drug plan, and most Medicare Advantage plans with drug coverage count.
There's one big limit. The Bridge sends you back to your regular plan if you have type 2 diabetes, moderate to severe sleep apnea, or the liver disease MASH with moderate to advanced scarring. The same goes if your prescription is meant to lower heart risk (CMS). Heart risk, sleep apnea and liver disease are the same uses the study found plans rarely cover, so the Bridge won't fill that gap for you.
One more thing to know: if you filled a GLP-1 through your Part D plan earlier in 2026, you can't use the Bridge this year (CMS).
What should you check before December 7?
- Search your exact drug name in Medicare's Plan Finder at medicare.gov/plan-compare. A plan can list Ozempic but not Wegovy, so don't just search the ingredient.
- Read the fine print if your plan does list it. Look for prior authorization and which diagnosis the plan requires.
- Check again even if you're covered now. Plans drop these drugs from one year to the next.
- If you use the Bridge, make sure your 2027 plan includes drug coverage.
- Call for help if you need it. You can reach Medicare at 1-800-MEDICARE (1-800-633-4227).
Our guide to checking a plan for GLP-1 coverage walks through how to read a drug list.
Final Takeaway
Medicare drug plans are allowed to cover Wegovy for heart and liver health and Zepbound for sleep apnea. A new study shows they almost never do, and coverage often disappears the next year. The $50 Bridge helps many people use these drugs for weight management through 2027, but it doesn't cover those other uses. If you rely on Wegovy or Zepbound, search your exact drug in Plan Finder before open enrollment ends on December 7.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
Does Medicare cover Wegovy for heart disease?
Medicare drug plans are allowed to cover Wegovy to lower heart attack and stroke risk, but a new study found almost no plans do. Check your plan's drug list for Wegovy by name before you enroll.
Does Medicare cover Zepbound for sleep apnea?
Plans can cover it for sleep apnea, but very few have. If you have moderate to severe sleep apnea, the $50 Medicare GLP-1 Bridge sends you to your regular plan instead.
Can I use the $50 Medicare GLP-1 Bridge if my plan covers Wegovy?
Not if you already filled a GLP-1 through your drug plan in 2026. And if the prescription is to lower heart risk, it goes through your plan, not the Bridge.
When does Medicare open enrollment end for 2027?
Open enrollment runs from October 15 to December 7, 2026. Your new coverage starts January 1, 2027.
What happens to the Medicare GLP-1 Bridge after 2027?
It's set to end on December 31, 2027. KFF says there's no clear path yet for coverage after that (KFF).
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Keep Reading
The Medicare GLP-1 Bridge now runs through 2027. See who qualifies, which plan types work, and what to check before December 7.
What Medicare, insurance, and federal policy signals really mean for GLP-1 coverage in 2026, including access rules, costs, and eligibility.
Confused about how Medicare may cover GLP-1 weight loss drugs after the TrumpRx deal Learn who may qualify, expected costs, and key dates until 2027.
Categories
Written by
Lauren PescarusLauren Pescarus is a team member with GLP Winner, where she works on marketing, content creation, and operations. She has over 10 years' experience in the content creation space, including in the GLP-1 space, where she works to stay on top of access news, research updates, and lifestyle tips guided by science.